MyMeds&Me Reportum® solution deployed by Pfizer Inc. for Pharmacovigilance in the U.S. market
London, UK, 9 March, 2015: MyMeds&Me, a leading SaaS provider of web-based adverse event and product quality complaint capture solutions for life sciences, today announced the deployment of the Reportum® solution across all Pfizer safety call centre sites for the U.S. market. This marks the signing of a hosting agreement with Pfizer to adopt the Reportum® solution via Software as a Service (SaaS) delivery. Pfizer has deployed the Reportum® solution from MyMeds&Me as the standard for the U.S. Safety Call Centre, to support prompt availability of high quality safety data from reporters, including consumers, patients and healthcare professionals.
Supporting Quotes:
“Improving processes with an easy to use electronic solution is key to maintaining high levels of quality by reducing potential transcription errors and managing the calls in a structured way to obtain as much information as possible with the first contact.”, said Pfizer VP, Rob Goodwin. “Our selection of the Reportum® solution reflects our commitment to streamline our call handling processes with state of the art electronic solutions.”
“We are delighted to announce the SaaS deployment and successful roll-out of the Reportum® solution across Pfizer Safety Call Centre sites for the United States”, said Andrew Rut, CEO at MyMeds&Me. “We believe that Pfizer’s commitment to standardisation on this market-leading, innovative solution underlines the significance of the Reportum® solution to the pharmacovigilance market”.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.
